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a b s t r a c t
Envelope glycoprotein 2 (E2) of hepatitis C virus contains 18 conserved cysteine (Cys) residues in its
ectodomain. By cysteine-alanine mutagenesis and function analysis, six Cys in H77 E2 (C494, C508, C552,
C564, C607 and C644) were found to be indispensable for recognition by conformation-dependent mAb
H53. Removal of any of these Cys residues did not affect E2 heterodimerization with E1, but notably
reduced E1E2 transmembrane transportation. These Cys together with C429 and C503 were required for
conformation-dependent mAb H48 recognition. All of the above Cys except C607 were required for H77
and Con1 E2 binding to CD81. None of individual mutation of above Cys affected the ability of E2 to
induce neutralizing antibodies in mice. Mouse antibodies mainly recognize E2 linear epitopes and are
unrelated to epitopes recognized by human E2 antibodies. The ﬁndings provide new insights for
understanding the biogenesis of functional HCV envelope proteins and HCV neutralizing immunity.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Hepatitis C virus (HCV) is an enveloped virus of the Flaviviridae
family with a single-stand positive RNA genome (Poynard et al.,
2003). HCV infection is a major cause of chronic liver disease that
frequently leads to cirrhosis and hepatocellular carcinoma (Kanwal
et al., 2011). Although the recent clinical application of two HCV
NS3 protease inhibitors improved the efﬁcacy of standard treat-
ment with pegylated alpha interferon combining ribavirin (Serfaty
et al., 2012; Poordad et al., 2011), drug resistant mutants have been
reported (Romano et al., 2012). More importantly, no vaccine is
available so far.
HCV envelope proteins, consisting of E1 and E2, form a non-
covalent heterodimer and are believed to be the basic functional
unit that mediates HCV cell entry (Lavie et al., 2007; Op De Beeck
et al., 2004). Increasing data demonstrated that E2 protein plays
a key role in mediating HCV interaction with cellular receptors
and inducing membrane fusion (Ploss and Evans, 2012; Zeisel
et al., 2011). E2 is a type-Ι transmembrane protein, within its
ectodomain contains 18 cysteine (Cys) residues strictly conserved
across the seven major genotypes. Krey et al. (2010) speciﬁed the
nine disulﬁde bonds formed by 18 cysteine residues within HCV
E2 ectodomain and predicted E2 tertiary organization as a class II
fusion protein related to ﬂavi- and alphaviruses with three non-
overlapping domains. Recently, McCaffrey et al. (2012) reported
that some cysteine residues perform indispensable role in HCVpp
incorporated E2 reactivity with a conformation dependent mono-
clonal antibody (mAb) H53, E2 binding to HCV receptor CD81 and
E1E2 heterodimerization, and all the cysteine residues in E2
protein of H77 strain of genotype 1a are required for cell entry
of HCVpp and HCVcc. Fenouillet et al. (2008) reported that E2
disulﬁde bonds masked antigenic domains and reducing status
contributed E2 to induce neutralizing antibodies.
In McCaffrey's report (2012), the characterization of cysteine
mutant E2 proteins was performed in the context of pseudopar-
ticles incorporated E2. Nevertheless, assembly characteristics of
HCVpp are basically different from authentic HCV particles. More
importantly, in this report, at least six cysteine mutations abol-
ished E2 incorporated into pseudoparticles, in this scenario, the
signiﬁcance of cysteine residues in E2 folding and function could
not be comprehensively assessed. In Fenouillet's report (2008),
effect of disulﬁde bonds on E2 antigenicity was investigated using
E2 protein treated with reducing agents, so the disulﬁde bonds
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that masked antigenic domains could not be speciﬁed. In this
study, we performed a comprehensive alanine-scanning mutagen-
esis of the 18 cysteine residues to investigate the functional role of
each cysteine residue for folding and transmembrane transporta-
tion of intracellular de novo synthesized E2 and for antigenicity of
E2 protein.
Results
Effect of Cys-Ala mutation on E2 reactivity with two conformation-
dependent mAbs
HEK 293 T cells were transfected with wild type or each Cys-
Ala mutant E1E2 plasmid and E2 and E1 protein was determined
by western blotting and GNA capture ELISA. The detective anti-
bodies used were E2 pAb, E2 mAb C6H and E1 mAb A4 (recogniz-
ing a linear epitope in E1 protein). None of the individual Cys-Ala
mutations affected E2 and E1 expression (Fig. 1A and B). The
cell lysates were then subjected to reactivity assay with two
conformation-dependent mAbs H53 and H48. H53 is speciﬁc for
a conformation epitope in correctly folded E2, no matter alone or
noncovalently associated with E1, which is believed to represent
native prebudding forms of the HCV envelope (Deleersnyder et al.,
1997). This epitope is independent of CD81-binding sites.
McCaffrey et al. (2012) recently determined the effect of Cys-Ala
mutation on H53 reactivity with HCVpp incorporated E2 protein.
This assay could not discriminate the effects caused by the
quantity of E2 incorporated into pseudoparticles or H53 reactivity
of E2 protein itself. In the present study, C494A, C508A, C552A,
C564A, C607A and C644A mutations nearly completely abrogated
E2 binding to H53, and C597A showed a signiﬁcantly reduced
reactivity with H53 (Fig. 1C). H48 is a conformation-dependent
mAb that disturbs interaction between HCV envelope protein and
HCV receptor CD81 (Op De Beeck et al., 2004). C429A, C494A,
C503A, C508A, C552A, C564A, C607A and C644A mutations
abolished E2 binding to H48, whereas the rest mutants displayed
reactivity to H48 comparable with wild type level (Fig. 1C).
It was worth noticing that mutation of C552, C494, C508 or
C564 abolished H53 reactivity, but mutation of their correspond-
ing partner C429, C486, C503 or C569 did not affect H53 recogni-
tion at all. Similarly, mutation of C494 or C564 abrogated H48
recognition, but neither mutation of their partner cysteine resi-
dues (C486 or C569) affected H48 reactivity. To investigate
whether that is caused by aberrant match of the unpaired cysteine
or alteration of local conformation, E2 proteins containing simul-
taneous Ala replacement of two cysteine residues within one
disulﬁde bond were prepared and their reactivity with two mAbs
was assayed. Results showed that disulﬁde bonds 1, 3, 4, and
5 were strictly indispensable for both H48 and H53 recognition.
Deletion of disulﬁde bond 7 did not affect H48 reactivity, but
moderately reduced H53 reactivity. Deletion of disulﬁde bond
8 reduced both H48 and H53 reactivity. Compared with individual
cysteine residues mutation in disulﬁde bond 8, pairwise mutation
of C607 and C644 partially recovered H53 and H48 recognition.
Disulﬁde bonds 2, 6 and 9 were dispensable for H48 and H53
reactivity (Fig. 1D).
Effect of individual Cys-Ala mutation on E2 binding to CD81
Interaction between HCV E2 and cellular CD81 is a pivotal step
in the complicated process of HCV entry. CD81 binding of Cys-Ala
mutant E2 in the context of full-length envelope protein was
detected using CD81 LEL capture ELISA. Similar with H53 reactivity
assay of HCVpp-incorporated E2 performed by McCaffrey et al.
(2012), the CD81 binding assay of HCVpp-incorporated E2 in that
report could not distinguish the effect between the quantity of
pseudoparticles incorporated E2 and CD81 binding activity of E2
itself. Based on CD81 LEL binding ELISA, C429A, C494A, C503A,
C508A, C552A, C564A, and C644A mutant of intracellular H77 E2
Fig. 1. Effect of Cys-Ala mutations on reactivity of H77 E2 protein with conformation-dependent mAbs H48 and H53. (A) HEK 293T cells were transfected with plasmids
containing wild type or individual Cys-Ala mutant H77 E1E2 expression plasmid and control mock plasmid, respectively. Forty-eight hr later, the cells were harvested, and
intracellular E1 and E2 were determined by western blotting. The detective antibodies were E2 pAb and E1 mAb A4, respectively, and GAPDH was assayed as an internal
standard. (B) Reactivity of E2 protein in 293T cell lysates with a linear epitope mAb C6H was detected via GNA capture ELISA. (C) Reactivity of E2 protein in 293T cell lysates
with mAbs H48 and H53 was detected via GNA capture ELISA. (D) HEK 293T cells were transfected with wild type or pairwise cysteine mutant H77 E1E2 plasmids. Reactivity
of E2 protein in 293 T cell lysates with mAbs C6H, H48 and H53 was analyzed via GNA capture ELISA. The ELISA data are the means7standard deviation of three
independent experiments.
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protein nearly completely lost CD81 binding activity, C459A and
C597A mutant decreased CD81 binding activity to about 55%,
C607A and C620A retained CD81 binding activity at about 30 and
25% of wild type level (Fig. 2A). A similar CD81 binding pattern
was observed for E2 protein of 1b subtype Con1 strain (Fig. 2B).
The results indicate that speciﬁc cysteine residues or disulﬁde
bonds basically contribute to CD81 binding of E2 protein among
different HCV genotypes.
In line with that the mAb H48 recognizes the conformation
epitope involved in CD81 binding, the CD81 binding proﬁle of the
Cys-Ala mutants is similar with H48 recognization, except for
C607A, which possessing low level of CD81 binding activity, but
could not be recognized by H48.
None of the Cys-Ala mutations affects intracellular noncovalent E1E2
heterodimerization
It has been reported that cysteine residues or disulﬁde bonds in
E2 protein involved in E1E2 heterodimer incorporated into HCVpp
(McCaffrey et al., 2012). However the role of cysteine residues in
E1E2 heterodimerization remains unclear. In this study, the mAb
H53 was used to immunoprecipitate intracellular E1E2 complex.
Consistent with the reactivity characteristics of mAb H53, E2
protein harboring single mutations of C494A, C508A, C552A,
C564A, C607A or C644A could not be precipitated by this antibody,
and C597A mutation markedly decreased heterodimer recognition
by H53 (Fig. 3A). Further 293T cells transfected with H77 E1E2
plasmids were lysed with a nondenaturing lysis buffer containing
NP40 or with a denaturing buffer containing 0.5% SDS as described
(Dubuisson et al., 1994), then the lysates were immunoprecipi-
tated with E2 pAb and the precipitated samples were separated by
SDS-PAGE under reducing conditions. The results showed that
treatment with 0.5% SDS signiﬁcantly decreased the amount of E1
in precipitations, but none of the H53 reactivity deﬁcient muta-
tions in E2 protein abated E1E2 noncovalent heterodimerization
(Fig. 3B). Co-immunoprecipitation of E1 and E2 in Huh7.5 cells
transfected with wild type or Cys-Ala mutant E1E2 plasmids
showed the similar results (data not shown).
Effect of Cys-Ala mutation on membrane transportation of E1 and E2
proteins
Both E1 and E2 are type I transmembrane glycoproteins that
form functional non-covalent heterodimer on the surface of HCV
particles as well as HCVpp (Op De Beeck et al., 2004). In this
aspect, transportation of intracellular E1E2 onto plasma mem-
brane may affect the formation of HCVpp. To investigate the effect
of Cys-Ala mutation on E1 and E2 transmembrane transportation,
293T cells were transfected with wild type or different mutant
E1E2 plasmids, cell surface-associated E1 and E2 were assayed by
ﬂow cytometry using E1 mAb A4, HVR1 polyclonal antibody and
E2 mAb H53, respectively. The results showed that individually
expressed E1 and E2 proteins could be transferred onto cell
surface, and co-expression with E2 notably increased E1 transpor-
tation (Fig. 4A). Anti-HVR1 antibodies recognize a linear epitope
located at aa16-24 in HVR1 (Guan et al., 2012), none of the Cys-Ala
mutations affected E2 protein reactivity with this antibody when
analyzed using GNA-capture ELISA (data not shown). Among 18
individual Cys-Ala mutations, C494A, C508A, C552A, C564A,
C607A and C644A mutant decreased the reactivity of anti-HVR1
antibodies with cell surface anchored E2 to less than 50% of wild
type E2 (Fig. 4B). Consistent with H53 reactivity with E2 in cell
lysates, these six Cys-Ala mutations led to substantial loss of H53
reactivity with cell surface associated E2 (Fig. 4C). Similarly, these
six Cys-Ala mutations decreased A4 reactivity with cell surface
associated E1 to the most extent (Fig. 4A). Overall, decreased H53
reactivity is accompanied with decreased HVR1 and A4 reactivity,
suggesting the native conformation recognized by H53 is required
for efﬁcient E1–E2 co-transportation. All the individual Cys-Ala
mutations in truncated E2-716 did not affect E2 secretion into
supernatants (as described below), suggesting Cys-Ala mutations
affecting the interaction between E2 and E1 and therefore their
transmembrane transportation.
Fig. 2. Effect of Cys-Ala mutations on E2-CD81 binding. HEK 293T cells were
transfected with plasmids containing wild type, Cys-Ala mutant H77 or Con1 E1E2
expression plasmid and control mock plasmid, respectively. Cells were lysed at 72 h
after transfection, and the lysates were normalized to equivalent amount of E2
protein and then used in E2-CD81 binding assay via ELISA. CD81 binding of mutant
E2 is expressed as percentage of that of wild type E2. (A) CD81 binding of Cys-Ala
mutant E2 of H77 strain. (B) CD81 binding of Cys-Ala mutant E2 of Con1 strain.
Results are means7standard deviations of three independent experiments.
Fig. 3. Effect of Cys-Ala mutations on intracellular E1E2 heterodimerization.
(A) The lysates of 293T cells transfected with plasmids containing wild type,
Cys-Ala mutant H77 E1E2 or mock vector were immunoprecipitated with E2 mAb
H53, then E1 and E2 proteins in the precipitations were respectively detected via
western blotting using E1 mAb A4 and E2 pAb. (B) HEK 293T cells tranfected with
H77 wild type or H53 reactivity deﬁcient mutant envelope plasmids were lysed
with a nondenaturing lysis buffer containing 0.5% NP-40 or with a denaturing
buffer containing 0.5% SDS. Cell lysates were immunoprecipitated with E2 pAb. The
precipitates were solubilized by heating for 10 min at 90 1C in SDS-PAGE sample
buffer and separated on a 10% polycrylamide gel under reducing conditions and
followed by immunoblotting analysis with E1 mAb A4 and E2 pAb.
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Single Cys-Ala mutation did not affect antigenicity of E2 ectodomain
and its ability to induce neutralizing antibodies in mice
E2 is the key protein that induces HCV neutralizing antibodies
(Faﬁ-Kremer et al., 2012). To investigate the effect of conformation
alteration by cysteine mutation on E2 antigenicity, the expression
plasmids of carboxyl terminal truncated E2 protein (E2-716) were
constructed, in which the transmembrane region across aa717–
746 were removed. A total of 18 E2-716 plasmids containing
individual Cys-Ala mutation and the wild type E2-716 plasmid
were respectively transfected into 293T cells, similar amount of E2
protein was detected in supernatants at 24 or 48 h post transfec-
tion (Fig. 5A). Eight plasmids encoding mutant E2 with decreased/
abrogated reactivity to mAb H53 or H48 and plasmid encoding
wild type E2-716 were used to immunize Balb/C mice for two
times at a 2-week interval. The serum antibodies against wild type
or mutant E2 were assayed 2 weeks after boost immunization. The
sera of mice immunized with wild type or mutant E2-716 plasmid
contained similar levels of antibodies against wild type E2 protein
(Fig. 5B), and the sera of mice immunized with wild type plasmid
produced similar levels of antibodies against autologous E2 and
mutant E2 proteins (Fig. 5C). HCVpp neutralization assay using IgG
fractioned from mouse sera showed that IgG antibodies of mice
immunized with wild type or various mutant H77 E2-716 blocked
autologous strain H77 pseudoparticles infection with similar
activity (Fig. 5D, upper panel) and same results were observed
for neutralization assay with heterologous strain Con1 pseudo-
particles, albeit with decreased efﬁciency compared with H77
strain (Fig. 5D, lower panel).
Mouse anti-E2 antibodies mainly recognize linear epitopes and are
unrelated to epitopes recognized by E2 antibodies of HCV-infected
persons
To determine the fraction of antibodies recognizing linear vs.
conformational epitopes, native and denatured E2 proteins were
respectively coated onto ELISA plates for antibody assay. Compared
with native E2, the reactivity of mAb anti-FLAG tag and mAb H52
(recognizing a linear epitope in E2) with denatured E2 decrease by
about 40%, suggesting denaturation may reduce E2 binding to GNA
lectin. As predicted, mAbs H53 and H48, recognizing conforma-
tional epitopes in E2 protein, nearly failed to bind with denatured
E2. Similar to H52 and anti-FLAG, the IgG fractions, either from
mice immunized with wild type E2 or cysteine mutant E2, showed
a similar decrease in reactivity with denatured E2 (Fig. 6A). The
data suggest that mouse antibodies induced by DNA immunization
mainly recognize linear epitopes in E2 protein.
A competition inhibition assay was performed to analyze the
difference of E2 epitopes recognized by mouse anti-E2 antibodies
and by human anti-E2 antibodies. For this purpose IgG were
respectively fractioned from ﬁfteen anti-HCV IgG positive serum
samples of HCV-infected individuals and three anti-HCV negative
donors. Using GNA capture ELISA, antibodies against H77 E2
protein could be detected in all the ﬁfteen anti-HCV IgG positive
samples (data not shown). The neutralization against H77 HCVpp
by human IgG samples were performed with 200 focus forming
units (FFU) psuedoparticles vs. 200 μg/ml IgG. Among these anti-
HCV positive IgG preparations, three samples showed neutraliza-
tion percentage more than 80% (higher neutralizing activity) and
seven samples showed neutralization percentage no more than
20% (lower neutralizing activity). The human IgG samples were
used in competition ELISA. Similar with anti-HCV negative IgG
samples, neither IgG samples with higher neutralizing activity nor
with lower neutralizing activity were able to competitively inhibit
mouse IgG (immunized with wild type E2 or E2/C429A and E2/
C494A mutants) binding to E2 protein (Fig. 6B). Similarly, human
E2 antibody binding to E2 protein could not be inhibited by mouse
E2 antibodies (data not shown). These results indicate the epitopes
in E2 protein recognized by mouse antibodies do not overlap with
epitopes recognized by human antibodies.
Discussion
McCaffrey et al. recently reported the role of individual cysteine
residues in H77 E2 protein in the context of HCVpp models,
however, the mechanisms involved in envelope proteins assembly
into authentic HCV particles are different from incorporation into
Fig. 4. Effect of Cys-Ala mutations on membrane transportation of E1 and E2 proteins. HEK 293T cells were transfected with wild type, Cys-Ala mutant H77 E1E2 expression
plasmids, E1 expression plasmid, E2 expression plasmid and mock plasmid (control), respectively. Cell surface associated E1 and E2 proteins were detected by ﬂow cytometry
using mAb A4 to E1 (A), pAb to HVR1 (B) and mAb H53 to E2 (C). The experiment was repeated three times and similar results were obtained. The binding percentage of E1
and E2 is expressed as mean MFI of that of E1 and E2 in the context of coexpressed wild type E1E2.
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pesudoparticles. In the present study we performed a compre-
hensive mutagenesis of individual cysteine residues of E2 protein
of genotype 1a strain H77 and genotype 1b strain Con1. None of
the individual Cys-Ala mutations in E2 protein in the context of E1
affect expression of E2 itself and E1 (Fig. 1A and B), permitting us
to dissect the effect of cysteine residues on E2 folding and
function. Both H53 and H48 are conformation-dependent mAbs
against E2 protein, the epitope of H48 is involved in CD81 binding
sites, but that of H53 is not (Deleersnyder et al., 1997; Op De Beeck
et al., 2004). H53 and H48 reactivity requires 6 common cysteine
residues (C494, C508, C552, C564, C607 and C644), and two
cysteine residues (C429 and C503) are additionally required for
H48 reactivity, suggesting CD81 binding requires more subtly
ﬁtted structure compare to H53 reactivity. In E2 model proposed
by Krey et al. (2010), the majority of the CD81 binding interaction
surface is located in domain I but is also partially overlapping
with domain III. In the present study, the cysteine residues
required for E2-CD81 binding of both H77 strain and Con1 strain
are dispersedly located in all the three domains. Among the six
cysteine residues in domain II, single mutation of three cysteine
residues (C494, C503, C508) substantially abolished CD81 binding
activity, and single mutation of C459 decreased CD81 binding by
more than 50%. The collective results consolidate that the three
domains cooperate to fold and maintain the spatial structure for
CD81 binding.
Single mutation of C429, C486, C503 and C569 did not affect
H53 and/or H48 reactivity or CD81 binding. However, mutation of
their partner cysteine residues C494, C508, C552 and C564 led to
loss of these functions, and pairwise mutation of these residues
also abolished H53 and H48 reactivity. The data suggest that the
single mutation of C552, C564, C494 and C508 may lead to
alteration of local conformation within E2 protein and in turn
ablate its function. On the contrary, either mutation of cysteine
residues that form disulﬁde bond 8 (C607–C644) abolished H53
and H48 reactivity, but simultaneous mutation of both cysteine
residues restored the recognition by both antibodies, which
Fig. 5. Antigenicity of E2 ectodomain bearing individual Cys-Ala mutation. (A) HEK 293T cells were transfected with wild type, Cys-Ala mutant H77 E2-716 plasmids or mock
plasmid, respectively, the soluble E2 protein in the culture supernatants at 24 and 48 h after transfection were determined via GNA capture ELISA. The mAb C6H was used as
detective antibody. (B) Mice were immunized with wild type, Cys-Ala mutant H77 E2-716 expression plasmid or mock vector for two times (six mice per group). The
antibodies against wild type E2 protein were assayed using GNA capture ELISA at 2 weeks after the boost immunization. Results from serially diluted mouse sera per group
are shown as the means7standard deviation of the absorbance at 450 nmwavelength. (C) HCV envelope proteins in lysates of HEK 293 T cells transfected with wild type or
Cys-Ala mutant H77 E1E2 plasmids were coated onto microplates using GNA, then anti-E2 IgG in sera (1:1000 dilution) of wild type E2-716 immunized mice was detected.
Results are shown as the means7standard deviation of the absorbance at 450 nm wave length. (D) The neutralizing activity of IgG preparations to H77 (upper panel) and
Con1 HCVpp (lower panel) were assayed. The percent of neutralization was determined by comparing viral infectivity in the presence of puriﬁed IgG with the mean
infectivity in the absence of mouse IgG. Data are the means of three independent experiments7standard deviation.
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suggests that phenotype caused by C607 or C644 mutation may be
due to formation of aberrant disulﬁde bonds.
It is reported that C508A mutation abolished E2 binding to
human mAb CBH-4G (a non-neutralizing conformation antibody)
and CBH-5 (a neutralizing conformation antibody that interrupts
E2-CD81 binding as H48 does), while C503A mutation eliminated
E2 binding to CBH-5, but retained its ability to react with CBH-4G
(Iacob et al., 2008). These observations are in line with our
ﬁndings and suggest that the effect of Cys-Ala mutation on E2
conformation observed in the present study may be a general
feature.
E1E2 complex formation follows two pathways. The dominant
pathway involves noncovalent interactions to form nonionic
detergent-stable E1E2 heterodimers (non-covalent), whereas
a minor fraction of the complexes are stabilized by intermolecular
disulﬁde bonds, aggregated, and most likely misfolded (Dubuisson
et al., 1994). The non-covalent E1E2 heterodimer is believed to be
the basic functional unit of the HCV envelope protein (Voisset and
Dubuisson, 2004). The E1E2 heterodimerization should occur in
endoplasmic reticulum (ER), from where the HCV particles bud
and release out of host cells. McCaffrey et al. (2012) reported that
mutation of some cysteine residues decreased and even abolished
retrovirion-incorporated E1E2 heterodimer. However, retrovirion-
incorporated E1E2 heterodimer could not represent intracellular
E1E2 heterodimeric status. In the present study, the six mutants
that abolished E2 binding to mAb H53 caused the absence of E1
and E2 in the precipitations when H53 was used as precipitating
antibody. Therefore, a denaturing buffer containing 0.5% SDS,
which is believed to destroy noncovalent interactions, but could
not interrupt intermolecular disulﬁde bonds between E1 and E2,
was used to treat native E1E2 prior to immuneprecipitation with
E2 pAb. As predicted, treatment of wild type E1E2 with 0.5% SDS
signiﬁcantly decreased E1 coprecipitated with E2 due to damage of
intermolecular noncovalent interactions. However, under native or
denatured conditions, E1E2 proteins containing H53 reactivity
deﬁcient mutation and wild type E1E2 showed similar precipitation
proﬁles, which suggests these mutations may not affect intracellular
E1E2 heterodimerization. It is also possible that non-covalent
Fig. 6. Epitope characterization of mouse anti-E2 antibodies by denatured E2 assay and competition ELISA. (A) Normalized native and denatured E2 protein were
respectively used to coat microplates, then their reactivity with mAbs H52, H53, anti-FLAG and IgG fractioned from sera of WT, mutant E2 or mock plasmid immunized mice
(at a concentration of 100 μg/ml) were detected by ELISA. The ﬁgures under the column show the decreased percentage of reactivity with denatured E2 compared to that of
wild type E2. NA means not applicable. (B) Crude cell extract containing E2 were used to coat microplates, then the plates were preincubated with serial dilutions of human
IgG samples for 2 h at RT, after extensive washing, IgG of mice immunized with wild type (◆) or mutant E2 (■, E2/C429A; ▲, E2/C494A) were added at a concentration of
100 μg/ml, respectively, then mouse antibody binding to E2 was detected. A total of three human IgG samples with higher HCV neutralizing antibodies, seven samples with
lower neutralization activity and three anti-HCV negative IgG samples were used in this assay and data are the means7standard deviation.
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heterodimerization occurs between E1 and an exposed hydropho-
bic part of the misfolded E2 protein.
Although E1 and E2 harboring ER retention signals in their
transmembrane domains, they can be transferred onto cell surface
and incorporated into pseudotyped HIV-1 particles (Drummer et al.,
2003). Consistent with this observation, in the present study E1 and
E2 proteins could be detected at the surface of transiently transfected
293 T or Huh7.5 cells when transfected with E1 or E2 expression
plasmid or E1E2 expression plasmid, and coexpression with E2
facilitated E1 transmembrane transportation. In line with mutation
of six cysteine residues (C494A, C508A, C552A, C564A, C607A,
C644A) abrogated H53 reactivity, individual mutation of these six
cysteine residues decreased E1 and E2 transmembrane transporta-
tion to the greatest extent, suggesting H53-reactive conformation is
important for E1E2 transmembrane transportation.
HCVpp bearing functional envelope proteins represents a valid
model for the study of HCV cell entry and antibody-mediated
neutralization (Bartosch et al., 2003; Faﬁ-Kremer et al., 2010).
Similar with the report by McCaffrey et al. (2012), all of the six
H53-reactivity deﬁcient Cys-Ala mutants failed to incorporate into
pseudoparticles, and the rest twelve mutants only moderately
reduced or did not affect E1/E2 incorporation into HCVpp (data not
shown), which is basically similar to the proﬁle of E1 and E2
transmembrane transportation (Fig. 4A–C). Together with the
characteristics of retrovirus budding (Cronin et al., 2005; Watson
et al., 2002.), the present data support that HCVpp assembly
occurs in cell membrane. In addition, all 18 cysteine residues were
indispensible for cell entry of both H77 and Con1 pseudoparticles
(data not shown), which consolidating the observation by
McCaffrey et al. (2012). Based on the observation that some
cysteine mutations did not affect E1E2 incorporation into pseudo-
particles and CD81 binding activity, but completely abrogated
HCVpp infectivity, it is possible that the spatial structure of E2
protein formed by nine correctly paired disulﬁde bonds is critical
for its conformation alteration induced by interaction with HCV
receptor CD81, claudin 1 or occludin, or by acid environment in
endosome for efﬁcient virus cell entry.
Envelope glycoproteins E1 and E2 are critical for host cell entry
and represent key targets for virus neutralization. Monoclonal
antibodies targeting both linear and conformational epitopes of
envelope glycoprotein E2 have been shown to inhibit entry of
HCVpp and infection of HCVcc (Wang et al., 2011). In the present
study, the soluble Cys-Ala mutants with abolished or markedly
decreased reactivity to mAb H53 or H48 induced similar levels of
antibodies to wild type E2 and autologous proteins and the IgG
preparations of mice immunized with wild or mutant E2 exerted
similar neutralizing activity to pseudoparticles of autologous H77
strain or heterologous Con1 strain. These data suggests the
conformation required for mAb H53, H48 and CD81 binding is
unimportant for induction of neutralizing antibodies in mice.
The proﬁles of antibody assay using native vs. denatured E2
proteins suggest E2 antibodies of mice immunized with wild or
Cys-Ala mutant E2 mainly recognize E2 linear epitopes, which may
account for why Cys-Ala mutations do not affect E2 antibody levels
in mice. Competition ELISA using IgG preparations of HCV infected
persons showed that the epitopes recognized by mouse E2 do not
overlap with epitopes recognized by human E2 antibodies, either
non-neutralizing or neutralizing antibodies. It is reported that
human neutralizing antibodies against HCV mainly target con-
formation epitopes in E2 protein (Wang et al., 2011), which is in
line with the present observation that human E2 antibodies could
not inhibit mouse antibody binding to E2 protein. The data
highlight the roles of species and immunization route for induc-
tion of HCV neutralizing antibodies.
In conclusion, the present study illustrated the roles of cysteine
residues in HCV E2 protein in the formation of intracellular E1E2
functional conformation, heterodimerization and transmembrane
transportation and the epitope characteristics of mouse antibodies
induced by immunization with wild type and cysteine mutant E2
proteins. The ﬁndings provide new insights into understanding the




Monoclonal antibodies (mAb) A4, H52, H53 and H48 were
kindly provided by Dr. Jean Dubuisson (Institute Pasteur de Lille,
Lille, France). The mAb C6H, recognizing a linear epitope RKHPEA-
TYTK in E2 of both H77 and Con1 strains, was prepared in this
laboratory. Rabbit anti-H77, Con1 HVR1 polyclonal antibodies
(pAb), HCV E2 pAb and HIV gag mAb anti-p24 were described
(Guan et al., 2012).
Plasmid constructs
The expression plasmid pCMV-E1E2 containing full-length
E1E2 sequences of the H77 strain genotype 1a or Con1 strain
genotype 1b were constructed as described (Guan et al., 2012).
In vitro mutagenesis was performed to introduce cysteine (TGC/T)
to alanine (GCC) substitutions using Site-Directed Mutagenesis Kit
(Stratagene). The resulting plasmids were conﬁrmed by DNA
sequencing (Invitrogen). To construct the secretary E2 expression
plasmids, the plasmids containing wild type or mutant full length
E1E2 were used as templates to amplify the truncated E2-716
(aa364-716 in H77 polyprotein) with a FLAG tag (DYKDDDDK) at
the carboxyl terminal.
Transfection
HEK 293T cells or Huh7.5 cells (kindly provided by C.M. Rice,
The Rockefeller University, NY) were transfected with HCV envel-
ope protein expression plasmids using Lipofectamine 2000 (Invi-
trogen) according to manufacturer's directions. The expression
products were detected by ELISA, FACS or western blotting.
Western blotting
HEK 293T cells transfected with HCV envelope plasmid were
lysed by ultrasonication as described (Guan et al., 2012). An equal
amount (20 μg) of total protein was resolved by electrophoresis in
a 10% sodium dodecyl sulfate (SDS)-polyacrylamide gel, protein
preparations were transferred onto nitrocellulose membranes
using a Trans-Blot apparatus (Bio-Rad). To detect HCV E1, E2 and
HIV gag, membranes were incubated with E1 mAb A4, E2 mAb
C6H or E2 pAb and HIV gag anti-p24, followed by a horseradish
peroxidase conjugated anti-mouse or goat IgG (Invitrogen). Immu-
noblots were revealed by enhanced chemiluminescence detection.
Flow cytometry
HEK 293T cells or Huh7.5 cells transfected with H77 envelope
plasmids or the empty vector were harvested and respectively
incubated with H77 HVR1 pAb, E2 mAb H53 and H52, E1 mAb A4
at room temperature (RT) for 1 h. After labeling with Alexa Fluor
488-conjugated anti-rabbit or mouse IgG (Invitrogen), ﬂuores-
cence positive cells and the mean ﬂuorescence intensity (MFI)
were quantiﬁed by a ﬂow cytometry (Cell Lab QuantaTM SC
Instrument, Beckman Coulter).
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ELISA assay of reactivity of HCV envelope proteins with antibodies
The reactivity of envelope proteins with E2 and E1 mAbs, HVR1
pAb was assayed by Galanthus nivalis agglutinin (GNA) capture
ELISA (Drummer et al., 2006). Brieﬂy, ELISA plates were coated
overnight at 4 1C with 1 μg/well of GNA (Sigma) in 0.05 M
carbonate–bicarbonate buffer, pH 9.6. Then plates were washed
with washing buffer (0.05% Tween 20, PBS) and nonspeciﬁc
binding sites were blocked with milk buffer (5% nonfat dry milk-
0.05% Tween 20-0.05% NaN3 in PBS) for 1 h at 37 1C. After
extensive washing, 293T cell extract containing E2 protein was
added to the GNA-coated plates. The plates were incubated for 2 h
at RT and then binding of anti-E2 mAbs H53, H48, C6H, E1 mAb A4
or HVR1 pAb was detected as described (Guan et al., 2012). To
investigate the effect of denaturation on E2 reactivity with E2
antibodies, 293T cell extract containing normalized E2 protein was
treated by a solution containing 0.5% SDS and 5 mM dithiothreitol
(DTT) at 56 1C for 10 min, then was used to coat ELISA plates for
antibody binding assay.
CD81 binding assay
CD81 binding assay was performed as described (Guan et al.,
2012; Tong et al., 2011). HEK 293T cells were transfected with wild
type or Cys-Ala mutated E1E2 plasmids or mock vector. Cells were
lysed by ultrasonication at 72 h after transfection. The lysates were
normalized to contain equivalent E2 protein and then used in
CD81 binding assay. Human CD81 large extracellular loop (LEL)
fused to His tag was expressed in E. coli and puriﬁed by afﬁnity
chromatography. ELISA plates were coated with 1 μg/well of
hCD81-LEL protein in phosphate-buffered saline (PBS) overnight
at 4 1C. The plates were then blocked with PBS containing 5% BSA
for 1 h at 37 1C. One hundred microliter of cell lysates containing
equivalent E2 protein were added to each well and incubated for
1 h at 37 1C. Bound E2 glycoprotein was detected using the mAb
C6H, followed by a horseradish peroxidase-conjugated goat anti-
mouse IgG (Invitrogen) and 3,3,5,5-teramethylbenzidine (TMB)
substrate. Absorbance values were determined at 450 nm after
stopping the reaction with 0.5 M sulfuric acid. CD81 binding level
of individual mutant E2 was expressed as a percentage to that of
wild type E2.
Immunoprecipitation
Immunoprecipitation was performed as described (Dubuisson
et al., 1994). Brieﬂy, HEK 293T cells or Huh7.5 cells tranfected with
H77 envelope plasmids were lysed with a nondenaturing lysis
buffer containing 0.5% NP-40 or with a denaturing buffer contain-
ing 0.5% SDS in 10 mM Tris–Cl (pH 7.5)-150 mM NaCl-2 mM
EDTA-20 μg of phenylmethylsulfonyl ﬂuoride per milliliter. Cell
lysates were clariﬁed by centrifugation at 14000g for 10 min
and precleared by an overnight incubation at 4 1C with protein
G-Sepharose (Roche). The supernatants were incubated with E2
pAb or mAb H53 at 4 1C for 1 h, then protein G-Sepharose (Roche)
was added and incubated overnight at 4 1C. Beads were centri-
fuged at the second day and washed with PBS three times. The
precipitates were solubilized by heating for 10 min at 90 1C in SDS-
PAGE sample buffer and separated on a 10% polycrylamide gel
under reducing conditions and followed by immunoblotting ana-
lysis with E1 mAb and E2 pAb.
Production and infection of HCVpp
Production of H77 and Con1 HCVpp was carried out as
described (Guan et al., 2012). Brieﬂy, 293T cells were transfected
with expression vectors encoding the viral components, i.e., HCV
E1E2 glycoproteins, lentiviral core proteins and packaging-
competent lentiviral transfer vectors containing enhanced green
ﬂuorescent protein reporter gene (EGFP) using lipofectamine
2000. At 48 h after transfection, culture supernatants containing
pseudoparticles were harvested and ﬁltered through 0.45-μm
pore-size membranes. Huh7.5 cells were seeded on 96-well plates
with a density of 8103 cells/well 12 h prior to HCVpp infection.
Then 10 μl viral supernatants were added to the cells and incu-
bated for 4 h. Supernatants were then removed and the infected
cells were kept in regular medium for 72 h before analysis of the
percentage of GFP-positive cells by ﬂow cytometry analysis.
Mice DNA immunization and HCVpp neutralization
Eight-week old female BALB/C mice were injected intramuscu-
larly with 100 μg of E2-716 expression plasmid or mock vector at
2-week intervals for a total of two times as described (Cao et al.,
2011). All the animals were sacriﬁced at 2 weeks after the boost
immunization. IgG antibodies against E2 protein were assayed
using ELISA as described above. Mouse IgG was fractioned using
protein A/G resin (GE Healthcare) and neutralization of H77 and
Con1 HCVpp was determined as described (Guan et al., 2012).
Mouse E2 antibody assay and competition ELISA
E2 protein were immobilized to ELISA plates by GNA capture as
described (Drummer et al., 2006), then serial dilutions of mouse
immune sera were added and incubated for 2 h at RT and then
mouse anti-E2 antibody was detected as described (Guan et al.,
2012).
For competition inhibition ELISA, IgG was fractioned from sera
of HCV-infected persons and anti-HCV negative donors. Anti-HCV
IgG was detected using commercial ELISA kits (KHB, Shanghai).
Competition of human E2 antibodies with mouse E2 antibodies for
E2 binding were performed by preincubation of serial dilutions of
human IgG samples in microplates coated with E2 protein and
followed by mouse E2 antibody assay as described above.
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